8-K: Salarius Pharmaceuticals Announces Promising Clinical Data for Seclidemstat in Blood Cancers

Salarius Pharmaceuticals reported a 43% overall response rate in a Phase 1/2 study of seclidemstat combined with azacitidine for patients with myelodysplastic syndrome and chronic myelomonocytic leukemia who had previously failed other treatments.

Summary

• Salarius Pharmaceuticals announced clinical data from a Phase 1/2 study of seclidemstat in combination with azacitidine.
• The study focused on patients with higher-risk myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) who had previously failed or relapsed after hypomethylating agent therapy.
• The data was presented at the 2024 European Hematology Association Annual Meeting.
• 14 patients were evaluable for efficacy, with a 43% overall response rate.
• The median overall survival was 18.5 months, with a median event-free survival of 7.2 months.
• The median follow-up time was 18.9 months from treatment initiation.
• 15 patients were evaluable for toxicity, with one dose-limiting toxicity observed.
• The study is ongoing, with the maximum tolerated dose not yet reached.

Sentiment

Score: 7

Explanation: The document presents promising clinical data, which is a positive sign. However, the company's financial situation and exploration of strategic alternatives introduce some uncertainty, preventing a higher score.

Positives

• The 43% overall response rate is promising for patients with limited treatment options.
• The median overall survival of 18.5 months is significantly longer than the typical 4-6 months seen after failing hypomethylating agents.
• The median event-free survival of 7.2 months is also encouraging.
• The adverse events observed were reported as manageable.

Negatives

• One dose-limiting toxicity was observed in the 750mg BID cohort.
• The study is still in the dose-escalation phase, and the maximum tolerated dose has not yet been reached.

Risks

• The study is still in an early phase, and further data is needed to confirm these results.
• The company is exploring strategic alternatives, which could create uncertainty.
• The company has limited financial resources and may need to seek additional funding.
• There is a risk that the strategic alternatives may not result in a transaction or enhance shareholder value.
• There is a risk that the company may need to seek other alternatives for restructuring and resolving its liabilities, including bankruptcy proceedings.

Future Outlook

The company is continuing to support its clinical programs while exploring strategic alternatives. The Phase 1 dose-escalation portion of the study will evaluate up to six dose levels of seclidemstat. The maximum tolerated dose will inform the Phase 2 portion of the study.

Management Comments

• William McVicar, Ph.D., Chairman of the Salarius Pharmaceuticals Board of Directors, stated that they are encouraged by the promising results at this early stage of the study.
• He also noted that patients who have failed prior treatments have a poor prognosis and are in desperate need of new treatment options.
• He agreed with the investigators that the results show promising early signs of activity in a high-risk MDS and CMML treatment failure population.

Industry Context

This announcement is significant as it provides promising data for a new treatment option for patients with MDS and CMML who have failed prior therapies. The results suggest that seclidemstat, in combination with azacitidine, could be a valuable addition to the treatment landscape for these challenging blood cancers.

Comparison to Industry Standards

• The reported median overall survival of 18.5 months is significantly higher than the typical 4-6 months seen after failure of hypomethylating agents, which is a common treatment for MDS and CMML.
• Comparable companies developing treatments for MDS and CMML include companies such as AbbVie with Venclexta and Bristol Myers Squibb with Onureg, however, these are not direct comparators as they are different treatment modalities.
• The 43% overall response rate is also a positive signal, as response rates for relapsed/refractory MDS and CMML are often lower with existing therapies.

Stakeholder Impact

• Shareholders may be positively impacted by the promising clinical data, but also face uncertainty due to the exploration of strategic alternatives.
• Patients with MDS and CMML may benefit from a new treatment option.
• Employees may be affected by the company's strategic review and potential restructuring.

Next Steps

• The Phase 1 dose-escalation portion of the study will continue to evaluate up to six dose levels of seclidemstat.
• Cohort 5 is currently enrolling, and cohort 6 will be the final cohort.
• The maximum tolerated dose will be determined and will inform the Phase 2 portion of the study.

Key Dates

Keywords

seclidemstat, myelodysplastic syndrome, chronic myelomonocytic leukemia, MDS, CMML, azacitidine, cancer therapy, hematology, clinical trial, LSD1 inhibitor